Hosted on MSN1mon
Equillium stock rallies 26% on itolizumab study data
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, with a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo. The primary endpoint of the ...
Morningstar1mon
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...
Hosted on MSN1mon
Equillium reports positive Phase 2 ulcerative colitis study data
The study, which was co-sponsored with Biocon (NSE:BION) Limited, included a total of 90 biologic-naïve patients who were randomized to receive either itolizumab, a placebo, or adalimumab ...
Yahoo Finance4d
Equillium, Inc. (EQ)
The data suggests high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added t ...
Nature4y
Restoring immune balance: Targeting CD6 to treat autoimmune and inflammatory disease
Equillium’s itolizumab downregulates T effector cell activity and trafficking to tissues. It is currently being tested against acute graft-vs-host disease (aGVHD), lupus nephritis, and ...
pharmaphorum3y
Equillium triples clinical pipeline with $329m Bioniz takeover
The La Jolla, California-based biotech licensed its first drug – itolizumab for graft-versus-host disease (GvHD), asthma and lupus nephritis – from Indian drugmaker Biocon in 2017. The Bioniz ...